Global Drug Device Combination Products Market Growth (Status and Outlook) 2024-2030

Global Drug Device Combination Products Market Growth (Status and Outlook) 2024-2030

Combination products are therapeutic and diagnostic products that combine drugs, devices and/or biological products, leading to safer and more effective treatments thanks to careful and precise drug targeting, local administration and individualized therapy. These technologies can especially benefit patients suffering from serious diseases and conditions such as cancer, heart disease, multiple sclerosis and diabetes, among others. On the other hand, drug-device combination products have also introduced a new dynamic in medical product development, regulatory approval and corporate interaction.

The global Drug Device Combination Products market size is projected to grow from US$ 34430 million in 2023 to US$ 50080 million in 2030; it is expected to grow at a CAGR of 5.5% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Drug Device Combination Products Industry Forecast” looks at past sales and reviews total world Drug Device Combination Products sales in 2023, providing a comprehensive analysis by region and market sector of projected Drug Device Combination Products sales for 2024 through 2030. With Drug Device Combination Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug Device Combination Products industry.

This Insight Report provides a comprehensive analysis of the global Drug Device Combination Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drug Device Combination Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drug Device Combination Products market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug Device Combination Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug Device Combination Products.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Drug Device Combination Products market by product type, application, key players and key regions and countries.

Segmentation by type
Drug-Eluting Stents
Prefilled Syringes
Wearable Injectors
Insulin Injector Drug
Others

Segmentation by application
Hospitals
Clinics
Ambulatory Surgical Centers
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Terumo
Stryker
Mylan
Medtronic
Allergan,
Boston Scientific
Novartis
Teleflex
BD
W.L.Core & Associates
Gerresheimer
Schott
Nipro

Please note: The report will take approximately 2 business days to prepare and deliver.